11/17/2005 GENEREX BIOTECHNOLOGY RETAINS WASHINGTON, D.C. – BASED LOBBYIST TO PURSUE OPPORTUNITIES FOR ORAL INSULIN & ITS AVIAN FLU VACCINE
TORONTO, Canada – November 17, 2005 – Generex Biotechnology Corporation (NasdaqSC: GNBT) announced today that it has retained Washington, D.C. – based Sandler, Travis & Rosenberg, P.A. (www.strtrade.com) to provide assistance in connection with the Company’s global clinical, regulatory, and commercialization program for Oral-lyn™, its proprietary oral insulin spray product, and in connection with the Antigen Express avian flu vaccine program. ST&R will assist the Company with White House and Congressional relations, relationships with administrative agencies, including the U.S. Food and Drug Administration, the Centers for Disease Control and Prevention, and the U.S. Department of Health & Human Services, and relationships with foreign governments. ST&R will also assist in the Company’s efforts to access governmental and private funding sources.
ST&R has been recognized as one of the preeminent international trade and government relations providers in the United States. ST&R brings together an aggressive team of Washington insiders and international strategists that includes legislative, regulatory, legal, economic, and industry experts.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist™ device. The Company’s flagship product, oral insulin (Oral-lyn™), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.
For more information, visit the Generex Web site at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," “forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Shayne Gilliatt of Generex Biotechnology Corporation, 1-800-391-6755, or
+1-416-364-2551; or Ken Sgro of CEOcast, Inc., 212-732-4300,
kensgro@ceocast.com, for Generex Biotechnology Corporation
» return to top
|
